Articles related to Oncology, Surgical

AI is enhancing surgical care through advanced preoperative planning, intraoperative decision-making, and postoperative monitoring, promising improved patient outcomes and operational efficiency.

Recent trials in NSCLC treatment reveal that perioperative immunotherapy, including combinations like nivolumab and chemotherapy, can significantly improve disease-free survival in early-stage resectable NSCLC.

Oncology practices can safeguard their income and operational stability by preparing for potential cyber incidents, emphasizing the importance of backup funding sources and secure claim submission methods.

A large-scale randomized controlled trial has identified significant prognostic factors for overall survival (OS) and cancer-specific survival (CSS) in localized prostate cancer, offering new insights into optimizing treatment strategies using surgery and radiotherapy.

In the CheckMate 77T trial, perioperative nivolumab plus chemotherapy followed by adjuvant nivolumab significantly improved event-free survival and pathological responses in patients with resectable NSCLC. The safety profile was consistent with known data, reinforcing nivolumab’s potential as a cornerstone in perioperative lung cancer therapy.

Enhertu, now FDA approved for HER2-positive solid tumors, shows a notable objective response rate across pivotal trials, providing a significant new option for patients with advanced disease stages.